First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age

BACKGROUND: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Gastrointest Oncol
Auteurs principaux: Petrillo, Angelica, Pappalardo, Annalisa, Calabrese, Filomena, Tirino, Giuseppe, Pompella, Luca, Ventriglia, Jole, Laterza, Maria Maddalena, Caterino, Marianna, Sforza, Vincenzo, Iranzo, Vega, Biglietto, Maria, Orditura, Michele, Ciardiello, Fortunato, Conzo, Giovanni, Molino, Carlo, De Vita, Ferdinando
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6776800/
https://ncbi.nlm.nih.gov/pubmed/31602329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.06.02
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires